1-3 of 3
Volker Lakner, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Imatinib (IM) in Combination with Hydroxyurea Showed Significantly Lower Major Molecular Response Rates at 6 Months but Similar MMR at 18 Months in Patients with CML1st CP Compared to IM Alone. Final Results of the CML2004 Study. NCT 02480608

Thoralf Lange, MD, Rainer Krahl, PhD, Ulrich von Grünhagen, MD, Haifa Kathrin Al-Ali, Schwarzer Andreas, MD, Kathleen Jentsch-Ulrich, MD, Claudia Spohn, MD, Volker Lakner, MD, Michael Assmann, MD, Christian Junghanss, MD, Markus Pfirrmann, Arthur Gil, PhD, Rüdiger Hehlmann, MD, Michael W. Deininger, MD PhD, Dietger Niederwieser, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1615.
https://doi.org/10.1182/blood.V130.Suppl_1.1615.1615
Published: 2017
Journal Articles

Results of a Prospective Randomised Open Label Phase III Study Comparing Rituximab Plus Mitoxantrone, Chlorambucile, Prednisolone Chemotherapy (R-MCP) Versus MCP Alone in Untreated Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) and Mantle-Cell-Lymphoma (MCL).

Michael Herold, MD, Rita Pasold, MD, Stefanie Srock, MD, Sabine Neser, MD, Dietger Niederwieser, MD, Andreas Neubauer, MD, Gottfried Dölken, MD, Ralph Naumann, MD, Thomas Fietz, MD, Mathias Freund, MD, Robert Rohrberg, MD, Klaus Hoeffken, MD, Astrid Franke, MD, Thomas H. Ittel, MD, Erika Kettner, MD, Ursula Haak, MD, Ullrich Mey, MD, Christian Klinkenstein, MD, Michael Assmann, MD, Ullrich von Gruenhagen, MD, Klaus Dachselt, MD, Helga Schwenke, MD, Dorothee Bleyl, MD, Heiner Wolf, MD, Sabine Hahnfeld, MD, Franz-Adolph Hoffmann, MD, Volker Lakner, MD, Peter Richter, MD, Detlev Hähling, MD, H. H. Wolf, MD, Henning Eschenburg, MD, M.-R. Clemens, MD, Norbert Grobe, MD
Journal: Blood
Blood (2004) 104 (11): 584.
https://doi.org/10.1182/blood.V104.11.584.584
Published: 2004
Journal Articles

Cost Evaluation of Rituximab Plus MCP vs. MCP Alone in Advanced Stage Indolent Non-Hodgkin’s-Lymphoma Based on a Randomized Controlled Multicenter Trial.

Klaus Hieke, Rita Pasold, MD, Sabine Neser, MD, Dietger Niederwieser, MD, Andreas Neubauer, MD, Gottfried Doelken, MD, Ralph Naumann, MD, Thomas Fietz, MD, Mathias Freund, MD, Robert Rohrberg, MD, Klaus Hoeffken, MD, Astrid Franke, MD, Thomas-Hein Ittel, MD, Erika Kettner, MD, Ursula Haak, MD, Ullrich Mey, MD, Christian Klinkenstein, MD, M. Assmann, MD, Ullrich von Gruenhagen, MD, Klaus Dachselt, MD, Helga Schwenke, MD, Dorothee Bleyl, MD, Heiner Wolf, MD, Sabine Hahnfels, MD, Franz-Adolph Hoffmann, MD, Volker Lakner, MD, Peter Richter, MD, Detlev Haehling, MD, H.H. Wolf, MD, H. Eschenburg, MD, N. Grobe, MD, M.-R. Clemens, MD, Michael Herold, MD
Journal: Blood
Blood (2004) 104 (11): 87.
https://doi.org/10.1182/blood.V104.11.87.87
Published: 2004